JP2021102633A5 - - Google Patents

Download PDF

Info

Publication number
JP2021102633A5
JP2021102633A5 JP2021047470A JP2021047470A JP2021102633A5 JP 2021102633 A5 JP2021102633 A5 JP 2021102633A5 JP 2021047470 A JP2021047470 A JP 2021047470A JP 2021047470 A JP2021047470 A JP 2021047470A JP 2021102633 A5 JP2021102633 A5 JP 2021102633A5
Authority
JP
Japan
Prior art keywords
binding protein
fragment
seq
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021047470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021102633A (ja
JP7140867B2 (ja
Filing date
Publication date
Priority claimed from JP2018559164A external-priority patent/JP6883590B2/ja
Application filed filed Critical
Publication of JP2021102633A publication Critical patent/JP2021102633A/ja
Publication of JP2021102633A5 publication Critical patent/JP2021102633A5/ja
Priority to JP2022067548A priority Critical patent/JP2022095910A/ja
Application granted granted Critical
Publication of JP7140867B2 publication Critical patent/JP7140867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021047470A 2016-01-29 2021-03-22 Pd-l1に結合する抗原結合性タンパク質 Active JP7140867B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022067548A JP2022095910A (ja) 2016-01-29 2022-04-15 Pd-l1に結合する抗原結合性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29
US62/288,912 2016-01-29
JP2018559164A JP6883590B2 (ja) 2016-01-29 2017-01-27 Pd−l1に結合する抗原結合性タンパク質

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018559164A Division JP6883590B2 (ja) 2016-01-29 2017-01-27 Pd−l1に結合する抗原結合性タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022067548A Division JP2022095910A (ja) 2016-01-29 2022-04-15 Pd-l1に結合する抗原結合性タンパク質

Publications (3)

Publication Number Publication Date
JP2021102633A JP2021102633A (ja) 2021-07-15
JP2021102633A5 true JP2021102633A5 (cg-RX-API-DMAC7.html) 2021-11-11
JP7140867B2 JP7140867B2 (ja) 2022-09-21

Family

ID=59386438

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559164A Active JP6883590B2 (ja) 2016-01-29 2017-01-27 Pd−l1に結合する抗原結合性タンパク質
JP2021047470A Active JP7140867B2 (ja) 2016-01-29 2021-03-22 Pd-l1に結合する抗原結合性タンパク質
JP2022067548A Pending JP2022095910A (ja) 2016-01-29 2022-04-15 Pd-l1に結合する抗原結合性タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018559164A Active JP6883590B2 (ja) 2016-01-29 2017-01-27 Pd−l1に結合する抗原結合性タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022067548A Pending JP2022095910A (ja) 2016-01-29 2022-04-15 Pd-l1に結合する抗原結合性タンパク質

Country Status (17)

Country Link
US (4) US10118963B2 (cg-RX-API-DMAC7.html)
EP (1) EP3408400B1 (cg-RX-API-DMAC7.html)
JP (3) JP6883590B2 (cg-RX-API-DMAC7.html)
KR (2) KR102927822B1 (cg-RX-API-DMAC7.html)
CN (2) CN116333124A (cg-RX-API-DMAC7.html)
AU (1) AU2017212717B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018015480A2 (cg-RX-API-DMAC7.html)
CA (1) CA3013051A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018002034A1 (cg-RX-API-DMAC7.html)
EA (1) EA037855B1 (cg-RX-API-DMAC7.html)
ES (1) ES2986360T3 (cg-RX-API-DMAC7.html)
IL (1) IL260846B2 (cg-RX-API-DMAC7.html)
MX (2) MX2018009228A (cg-RX-API-DMAC7.html)
PH (1) PH12018501611A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201806496SA (cg-RX-API-DMAC7.html)
TW (1) TWI760323B (cg-RX-API-DMAC7.html)
WO (1) WO2017132562A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
ES2986360T3 (es) * 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2019180201A2 (en) * 2018-03-22 2019-09-26 Keires Ag Antagonistic antigen binding proteins
CA3095498A1 (en) 2018-04-09 2019-10-17 Origincell Therapeutics Co., Ltd. Anti-pd-l1 antibody and use thereof
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2021525806A (ja) * 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド 疾患または状態を処置するための組成物およびそれらの使用
WO2020038379A1 (en) * 2018-08-20 2020-02-27 1Globe Biomedical Co., Ltd. Novel cancer immunotherapy antibody compositions
WO2020123543A2 (en) * 2018-12-11 2020-06-18 Sanford Burnham Prebys Medical Discovery Institute Models and methods useful for the treatment of serrated colorectal cancer
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
CA3136453A1 (en) 2019-04-18 2020-10-22 Qlsf Biotherapeutics Inc. Humanized anti-pd-l1 antibodies
US12404333B2 (en) 2019-08-29 2025-09-02 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
CA3183673A1 (en) * 2020-06-26 2021-12-30 Robert Allen Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
US20230338574A1 (en) 2020-09-02 2023-10-26 Mayo Foundation For Medical Education And Research Antibody-nanoparticle complexes and methods for making and using the same
US20230416369A1 (en) 2020-11-16 2023-12-28 Immuneoncia Therapeutics, Inc. Biomarker for predicting therapeutic responsiveness to cancer immunotherapeutic agent and use thereof
WO2022235127A1 (ko) 2021-05-07 2022-11-10 주식회사 이뮨온시아 Cd47 및 pd-l1에 특이적으로 결합하는 이중특이적 항체
AU2022290563A1 (en) 2021-06-09 2024-01-25 Sofusa Holdings Llc Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
EP4590328A2 (en) * 2022-09-19 2025-07-30 Sonoma Biotherapeutics, Inc. Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
WO2025183487A1 (en) * 2024-02-29 2025-09-04 Yuhan Corporation Anti-tigit/anti-pd-l1 bispecific antibody and use thereof
IL323020A (en) 2024-04-13 2026-03-01 Immuneoncia Therapeutics Inc Neoadjuvant immunotherapy with pd-l1 inhibitor in treating cancer
KR102961530B1 (ko) 2024-04-13 2026-05-08 주식회사 이뮨온시아 암 치료를 위한 pd-l1 저해제를 이용한 신보조요법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2162149B1 (en) 2007-06-01 2013-11-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA3175360C (en) * 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
JP6759104B2 (ja) * 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
ES2986360T3 (es) * 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1

Similar Documents

Publication Publication Date Title
JP2022058932A5 (cg-RX-API-DMAC7.html)
JP2016521692A5 (cg-RX-API-DMAC7.html)
TWI659969B (zh) 一種抗pd-1的單株抗體及其獲得方法
TWI821474B (zh) Cd3抗體及其藥物用途
CN108250296B (zh) 全人源抗人pd-l1单克隆抗体及其应用
JP2018510151A5 (cg-RX-API-DMAC7.html)
JP2018504105A5 (cg-RX-API-DMAC7.html)
JP2021502104A5 (cg-RX-API-DMAC7.html)
JP2019507183A5 (cg-RX-API-DMAC7.html)
CN112969476B (zh) 多特异性蛋白分子
JP2015519375A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
JP2021532058A5 (cg-RX-API-DMAC7.html)
JP2019214586A5 (cg-RX-API-DMAC7.html)
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2020500523A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
HRP20220131T1 (hr) Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste
JP2018532766A5 (cg-RX-API-DMAC7.html)
JP2012501669A5 (cg-RX-API-DMAC7.html)
JP2019507135A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
RU2017121326A (ru) Общие легкие цепи и способы их применения
RU2009128064A (ru) Антитела к cd44
JP2011526785A5 (cg-RX-API-DMAC7.html)